Schütt W, Grüttner C, Teller J, Westphal F, Häfeli U, Paulke B, Goetz P, Finck W
The Jikei University School of Medicine, Tokyo, Japan.
Artif Organs. 1999 Jan;23(1):98-103. doi: 10.1046/j.1525-1594.1999.06278.x.
The magnetic guidance of antiplastic and antibacterial agents as well as x-ray and MRI contrast substances in vivo by means of magnetic particles has been attempted repeatedly during the last 2 decades with more or less success. When using microparticles, the circulation time in the blood, the biodistribution, and to a greater or lesser extent, the specific targeting are determined by the uniformity of size, chemical composition, surface modification, and the electric surface charge. The electrophoretic mobility is an important parameter for the prediction of the usefulness of the prepared particle, modified by chemical and biological molecules. For its success, radionuclide therapy depends on the critical relationship between the amount of radioactive isotopes in the target tissue and in critical normal tissue. Because the implementation of radioimmunotherapy for the treatment of cancer has proven to be considerably more difficult than initially anticipated, we propose the use of magnetic nanospheres for the well directed delivery of radionuclides to a tumor after the intravenous administration of the biodegradable colloidal suspension.
在过去20年里，人们多次尝试利用磁性颗粒在体内对抗塑剂、抗菌剂以及X射线和MRI造影剂进行磁引导，或多或少取得了一些成功。使用微粒时，其在血液中的循环时间、生物分布以及在一定程度上的特异性靶向作用，取决于颗粒大小的均匀性、化学成分、表面修饰以及表面电荷。电泳迁移率是预测经化学和生物分子修饰后所制备颗粒有效性的一个重要参数。放射性核素治疗的成功取决于靶组织和关键正常组织中放射性同位素含量之间的关键关系。由于事实证明，实施放射免疫疗法治疗癌症比最初预期的要困难得多，因此我们建议在静脉注射可生物降解胶体悬浮液后，使用磁性纳米球将放射性核素精确地递送至肿瘤部位。
